Researchers at Queen’s University Belfast have Developed a Vaginal Ring Capable of Providing Sustained Delivery of OB-002 (5P12-RANTES) for HIV Prevention
OTTAWA, Feb. 12, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that researchers at the School of Pharmacy, Queen’s University Belfast, have published an article in the Journal of Controlled Release describing a new intravaginal ring (IVR) design offering sustained delivery of the antiretroviral protein OB-002 (also known as 5P12-RANTES). In a sheep pharmacokinetic model, the concentrations of OB-002 released from the IVR into the vaginal compartment were at least 50 and up to 50,000 times the reported in vitro IC50 value for HIV infection. The IVR is manufactured from silicone elastomer using simple and scalable injection moulding technology, and the process can be easily modified to allow coformulation of multiple drug substances. This could facilitate the development of a combination IVR with both contraceptive and anti-HIV activity.
“Development of an OB-002 IVR that can deliver protective concentrations of OB-002 to the vaginal mucosa is an important first step in providing new options for women who want to protect themselves from HIV infection,” said Dr. Ian McGowan, Chief Scientific Officer for Orion Biotechnology.
Professor Karl Malcolm, who lead the team at Queen’s University Belfast, added, “We are delighted by these preliminary data. This new ring design – which was designed from the outset for ease and scalability of manufacture – offers the ability to combine multiple drug actives. Combinations of antiretrovirals are an obvious option. But, perhaps even more exciting is the possibility of combining OB-002 with a contraceptive drug to provide women with a multipurpose prevention technology IVR.”
“Our OB-002 gel will be entering Phase 1 clinical evaluation in Q3 2019 and so it is very exciting that a second potential formulation platform is already available for later stage development. Orion Biotechnology is committed to providing women with options for HIV prevention and we look forward to exploring ways in which an OB-002 IVR could move into the clinic,” added Mark Groper, CEO at Orion Biotechnology.
Title: “Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES”
DOI Number: https://doi.org/10.1016/j.jconrel.2019.02.003
Cite the article: McBride, J.W., Boyd, P., Dias, N., Cameron, D., Offord, R.E., Hartley, O., Kett, V.L., Malcolm, R.K., 2019. Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES. J. Control. Release 298, 1–11.
About Orion Biotechnology Canada, Ltd.
Orion Biotechnology Canada Ltd, is a privately held pharmaceutical company founded on the vision of radically improving the health of the global population through successful treatment and prevention of the most serious chronic illnesses and life-threatening diseases. Since 2011, Orion has been developing a robust pipeline of potential products based on novel formulations discovered in different parts of the world. Our close ties to diverse institutions and experts around the globe continue to stimulate the rapid discovery of promising new treatments. With operations in North America, Europe and Asia, Orion brings together innovative technologies from some of the world’s leading research institutions, such as the Mintaka Research Foundation and the Center for Public Health Research at Nanjing University. Learn more at www.orionbiotechnology.com.
This press release contains forward-looking information, which reflects Orion’s current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond Orion’s control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. These forward-looking statements are made as of the date of this press release and, except as expressly required by applicable law, Orion assumes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
Contact: Ross MacLeod
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
The Delhi High Court in India has issued an injunction, restraining Sinopharm Weiqida from exporting its “Amoxycillin Trihydrate” product to India, as it infringes the patent of Centrient Pharmaceuticals19.2.2019 09:00:00 | Pressemelding
The High Court also found Sinopharm Weiqida guilty of Contempt of Court for failing to follow the previously granted preliminary injunction order ROTTERDAM, the Netherlands, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Centrient Pharmaceuticals (“Centrient”), the leading manufacturer of beta-lactam antibiotics, and a provider of next generation statins and anti-fungals, announced that the Delhi High Court in India has granted an injunction against Sinopharm Weiqida Pharmaceuticals and Sinopharm India, restricting the export and/or import into India of its active pharmaceutical ingredient (API) amoxicillin trihydrate. In addition, the Delhi High Court also found Sinopharm Weiqida prima facie guilty of contempt of Court for illegally importing amoxicillin active ingredients in contravention of the previously granted preliminary injunction in place in India since April 2017. The Court further found that Sinopharm Weiqida has infringed the patent of Centrient. Centrient, and its wholly owned subsidia
New Milestone for Cansativa Towards “EU GxP Innovation Hub”19.2.2019 07:15:00 | Pressemelding
Northern Swan invests millions in pharma startup Cansativa FRANKFURT, Germany, Feb. 19, 2019 (GLOBE NEWSWIRE) -- Northern Swan, a New-York based investment firm, has invested several million euros in Cansativa GmbH, in order to further accelerate the growth of the company and its integration into the wider European market. Cansativa will use this investment to expand its current facilities to become a “EU GxP Innovation Hub” and fulfillment center for medical cannabis. This way, Cansativa helps promote the professionalization of the entire medical cannabis industry in Europe from its location in Frankfurt am Main, Germany. The new site will serve as the EU hub for the growing industry, granting pharmaceutical companies from all over the world access to the rapidly growing European market. Cansativa is poised to lend its support as a reliable, independent full-service GxP partner. "Unlike the majority of our competitors, we operate independently of third-party contractors – Ever since w
Juniper Systems Limited Launches New Cedar CT8 Rugged Tablet19.2.2019 05:16:00 | Pressemelding
Fully-Rugged Tablet Provides Global Connectivity, Better Performance BIRMINGHAM, United Kingdom, Feb. 18, 2019 (GLOBE NEWSWIRE) -- Juniper Systems Limited today announced the release of the Cedar CT8™ Rugged Tablet, a high-performance Android® tablet made for rugged environments. The CT8 – the third Cedar tablet from Juniper Systems™ – marks a major upgrade in performance and GPS capability from its predecessor, the Cedar CT7G Rugged Tablet (2017 release). Packed behind its 8-inch high-visibility display is a Qualcomm Snapdragon 8-core processor running Android 8.1 with full Google® Mobile Services. This highly-efficient processor results in lower power consumption, less heat generated, and better overall performance. ‘The CT8 is fast, affordable, and it’s got rugged bones’, said Cody Draper, Juniper Systems’ Cedar product manager. ‘Job sites that need a formidable, cost-effective rugged tablet will find the CT8’s features easily meet and exceed those needs’. The CT8 Rugged Tablet also
INVNT No Longer Involved, As Bethel Woods Music and Culture Festival Changes Direction and Becomes Three Separate Events18.2.2019 23:37:00 | Pressemelding
NEW YORK, NY, Feb. 18, 2019 (GLOBE NEWSWIRE) -- INVNT, the global live brand storytelling agency™ today announces that it will not be producing Bethel Woods Music and Culture Festival: Celebrating the golden anniversary at the historic site of the 1969 Woodstock festival. The festival, which was planned for August 16-18, 2019 at Bethel Woods Center for the Arts, will now comprise three separate events over three days, and forms part of the venue’s Season of Song & Celebration commemorations, a year-long schedule of exhibits, programs and events. Scott Cullather, CEO, INVNT explained that the agency is proud of its support and contributions to the celebration plans and the global awareness that its efforts brought to Bethel Woods Center for the Arts, as a result. "INVNT will not be involved in the new format and we wish Bethel Woods and Live Nation, as well as the organizers of the other 50th anniversary celebrations taking place around the world, the very best," he said. "Bethel Woods
Align Technology Launches New iTero Element 5D Imaging System for Comprehensive Preventative and Restorative Oral Care at IDS18.2.2019 12:00:00 | Pressemelding
SAN JOSE, Calif., Feb. 18, 2019 (GLOBE NEWSWIRE) -- First intraoral scanner with near-infrared imaging (NIRI) technology that scans the internal structure of a tooth (enamel & dentin) in real time1. First integrated dental imaging system that simultaneously records 3D, intra-oral color and NIRI, and enables comparison over time using iTero® TimeLapse1. NIRI technology of the iTero Element® 5D system aids in detection and monitoring of interproximal caries lesions above the gingiva without using harmful radiation1. New web-based interface MyiTero.com complements visualization of the iTero Element 5D system. Limited-release direct doctor-lab workflow automatically sends scan to lab of choice. Align Technology, Inc. (NASDAQ: ALGN) today announced that it is launching the iTero Element 5D Imaging System, which provides a new comprehensive approach to clinical applications, workflows and user experience that expands the suite of existing high-precision, full-color imaging and fast scan time
General Electric Company: Dividend Declaration18.2.2019 08:00:00 | Pressemelding
FAIRFIELD, Conn., Feb. 18, 2019 (GLOBE NEWSWIRE) -- GE Board of Directors Authorizes Regular Quarterly Dividend The Board of Directors of GE (NYSE: GE) today declared a $0.01 per share dividend on the outstanding common stock of the Company. The dividend is payable April 25, 2019 to shareowners of record at the close of business on March 11, 2019. The ex-dividend date is March 8, 2019. About GE GE (NYSE:GE) drives the world forward by tackling its biggest challenges. By combining world-class engineering with software and analytics, GE helps the world work more efficiently, reliably, and safely. For more than 125 years, GE has invented the future of industry, and today it leads new paradigms in additive manufacturing, materials science, and data analytics. GE people are global, diverse and dedicated, operating with the highest integrity and passion to fulfill GE's mission and deliver for our customers. www.ge.com GE's Investor Relations website at www.ge.com/investor and our corporate b